Joshua Kim, MD
Ophthalmology · New York, NYNPI 1740391952
Payments from drug & device makers
Across 683 payments — averaging $991.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$338K
- AbbVie$164K
- Aerie Pharmaceuticals, Inc.$77K
- Alcon Research LLC$33K
- Ivantis, Inc$24K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$20K
- plus $22K from 14 others
Across 4 payments — averaging $2641.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$10K
- Glaukos Corporation$311
- AbbVie$5
What the payments were for
- Consulting fees$23,52812%
- Speaking & faculty fees$133,73367%
- Travel & lodging$15,9048%
- Food & beverage$12,7566%
- Gifts$1000%
- Other$13,9037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 293 | $337,515 |
| AbbVie(2 entities) | 186 | $164,295 |
| Aerie Pharmaceuticals, Inc. | 75 | $76,967 |
| Alcon Research LLC | 5 | $33,357 |
| Ivantis, Inc | 10 | $23,617 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $19,949 |
| Alcon | 28 | $16,047 |
| Bausch & Lomb Americas Inc. | 12 | $3,248 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $709 |
| Sight Sciences, Inc. | 14 | $337 |
| Rxsight Inc | 3 | $270 |
| Tarsus Pharmaceuticals, Inc. | 2 | $244 |
| NEW World Medical,inc. | 4 | $217 |
| Nova Eye, Inc. | 1 | $128 |
| Sun Pharmaceutical Industries Inc. | 2 | $115 |
| Apellis Pharmaceuticals, Inc. | 1 | $106 |
| Rayner Intraocular Lenses Limited | 3 | $50 |
| Omeros Corporation | 2 | $38 |
| Halozyme Inc | 1 | $17 |
| Lensar, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$49,290
- Rhopressa$43,289
- XEN GLAUCOMA TREATMENT SYSTEM$33,978
- LUMIGAN$33,520
- VYZULTA$22,450
- COMBIGAN$15,611
- Hydrus Microstent$14,257
- iDose$12,323
- XEN$10,024
- iStent inject Trabecular Micro-Bypass Stent System$9,131
- ALPHAGAN P$3,500
- iStent Trabecular Micro-Bypass Stent System$1,431
- DURYSTA$1,367
- SIMBRINZA$1,140
- Travoprost Intraocular Implant - iDose$450
- Tecnis IOL$278
- XDEMVY$244
- Kahook Dual Blade$155
- Clearpath$155
- Ahmed Glaucoma Valve$155
How this compares
$677,241 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 288 | $174,700 |
| Alphagan PBrimonidine Tartrate | 151 | $68,215 |
| RhopressaNetarsudil Mesylate | 106 | $68,051 |
| RocklatanNetarsudil Mesylat/Latanoprost | 133 | $67,490 |
| VyzultaLatanoprostene Bunod | 132 | $63,824 |
| CombiganBrimonidine Tartrate/Timolol | 104 | $46,491 |
| Prednisolone Acetate | 1,219 | $41,048 |
| IlevroNepafenac | 95 | $35,380 |
| AzoptBrinzolamide | 37 | $19,423 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 62 | $14,915 |
| Latanoprost | 1,251 | $14,001 |
| RestasisCyclosporine | 16 | $13,387 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 74 | $11,962 |
| Brinzolamide | 60 | $11,396 |
| ProlensaBromfenac Sodium | 31 | $10,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $164,295 | $302,793559 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $76,967 | $135,541239 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $3,248 | $63,824132 claims |
| AlconAzopt, Simbrinza | $16,047 | $29,62468 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $19,949 | $13,45051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Eric RosenbergNew York$526K
- Ashley BrissetteNew York$452K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.